Keeping Lead in Migraine Drug Race, Amgen Touts Data, Preps FDA Filing

The first of a new group of drugs meant to prevent migraines, not just treat their symptoms, could be headed for FDA review next year. Amgen (NASDAQ: AMGN), of Thousand Oaks, CA, said Wednesday that a…
Read the full story: Xconomy